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Chagas’ disease, African sleeping sickness and leish-
maniasis (cutaneous, mucocutaneous and visceral) are
neglected diseases afﬂicting millions of people world-
wide. All of the drugs used to treat these neglected dis-
eases suffer from deﬁciencies such as poor efﬁcacy,
drug resistance, toxicity or high cost of treatment [1].
The parasitic protozoa causing these diseases belong to
the order Kinetoplastida, and comparative genomic
and biochemical studies have revealed a number of
unique metabolic pathways that are being exploited
for drug discovery [2]. One of these involves trypano-
thione [N
1,N
8-bis(glutathionyl)spermidine] and trypa-
nothione reductase, which replaces not only
glutathione⁄glutathione reductase but also thioredoxin⁄
thioredoxin reductase in mammalian cells [3]. Together
with the type I and II tryparedoxin peroxidases [4–6],
trypanothione is pivotal in defence against oxidative
stress induced by host cell defence mechanisms [7–9] or
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Glutathionylspermidine is an intermediate formed in the biosynthesis of
trypanothione, an essential metabolite in defence against chemical and oxi-
dative stress in the Kinetoplastida. The kinetic mechanism for glutathionyl-
spermidine synthetase (EC 6.3.1.8) from Crithidia fasciculata (CfGspS)
obeys a rapid equilibrium random ter-ter model with kinetic constants
KGSH = 609 lm, KSpd = 157 lm and KATP = 215 lm. Phosphonate and
phosphinate analogues of glutathionylspermidine, previously shown to be
potent inhibitors of GspS from Escherichia coli, are equally potent against
CfGspS. The tetrahedral phosphonate acts as a simple ground state ana-
logue of glutathione (GSH) (Ki   156 lm), whereas the phosphinate
behaves as a stable mimic of the postulated unstable tetrahedral intermedi-
ate. Kinetic studies showed that the phosphinate behaves as a slow-binding
bisubstrate inhibitor [competitive with respect to GSH and spermidine
(Spd)] with rate constants k3 (on rate) = 6.98 · 10
4 m
)1Æs
)1 and k4 (off
rate) = 1.3 · 10
)3 s
)1, providing a dissociation constant Ki = 18.6 nm.
The phosphinate analogue also inhibited recombinant trypanothione syn-
thetase (EC 6.3.1.9) from C. fasciculata, Leishmania major, Trypanosoma
cruzi and Trypanosoma brucei with Ki
app values 20–40-fold greater than
that of CfGspS. This phosphinate analogue remains the most potent
enzyme inhibitor identiﬁed to date, and represents a good starting point
for drug discovery for trypanosomiasis and leishmaniasis.
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addition, novel trypanothione-dependent enzymes have
been identiﬁed, such as trypanothione S-transferase
[12] and glyoxalase I and II [13–15], that are probably
involved in defence against chemical stress. The perti-
nence of the effects caused by decreasing trypanothi-
one content and thus increased chemical stress
highlight the signiﬁcance of the biosynthetic enzyme(s)
of trypanothione as drug target(s) [16].
Trypanothione is synthesized in these medically
important parasites from glutathione (GSH) and sper-
midine (Spd) by a monomeric C-N ligase [trypanothi-
one synthetase (TryS), EC 6.3.1.9], in a two-step
reaction with glutathionylspermidine as an intermedi-
ate [17–20]. Both trypanothione reductase and TryS
have been shown to be essential for parasite survival
[21–25]. However, in the insect parasite, Crithidia
fasciculata, TryS forms a heterodimer with the bi-
functional glutathionylspermidine synthetase⁄amidase
(GspS, EC 6.3.1.8⁄GspA, EC 3.5.1.78) [26]. Previous
work suggested that each biosynthetic enzyme indepen-
dently adds successive molecules of GSH to Spd to
make trypanothione [26,27]. However, recombinant
TryS from C. fasciculata (CfTryS) has been reported
subsequently to catalyse both steps of trypanothione
synthesis [28]. Although a gene for GspS has not been
identiﬁed in Trypanosoma brucei, there is a pseudogene
in Leishmania major (accession number AJ748279) [19]
and putative genes for GspS within the genomes of
Leishmania infantum (accession number AM502243)
and Trypanosoma cruzi (accession number EAN98995)
that remain to be functionally characterized. Genome
sequencing information has also highlighted the pres-
ence of GSPS in a range of enteric pathogens such as
Salmonella and Shigella [29,30]. The mechanism and
physiological function of this protein are unknown,
but in Escherichia coli it is proposed to be involved in
regulation of polyamine levels during growth [31], and
a similar function has been postulated for C. fasciculata
GspS (CfGspS) [32]. Glutathionylspermidine accumu-
lates only under stationary-phase conditions, and an
alternative proposal is that it may be more effective in
protecting DNA from oxidant damage than GSH [33].
A previous lack of structural information on this
important class of enzymes has been recently resolved
with the reported crystal structure of GspS from
E. coli (EcGspS), which includes the enzyme in com-
plex with substrate, product and inhibitor [34].
Preliminary enzyme characterization has previously
been described for CfGspS [35], as well as kinetic studies
on the partially puriﬁed native enzyme using an HPLC
method [36,37]. Other studies have identiﬁed phosphon-
ic and phosphinic acid derivatives of GSH as moderate
inhibitors of CfGspS [38]. The most active of these was
a phosphonic analogue of GSH (c-l-Glu-l-Leu-Gly
P),
which displayed linear noncompetitive inhibition
(Ki   60 lm). This analogue was further improved as
an inhibitor of CfGspS by the substitution of the glycine
moiety with amino acid analogues, such as diamino-
propionic acid (Ki   7 lm) [39]. Although these inhibi-
tors are excellent lead compounds for drug design
against the trypanosomatid parasites, none, as yet, has
yielded Ki values in the nanomolar range.
Proteases that catalyse the direct addition of water
to proteins or peptides proceed via an unstable tetrahe-
dral intermediate. These enzymes are inhibited by
phosphorus-based stable mimics of the intermediate
[40]. Such high-afﬁnity analogues are termed transition
state analogues or intermediate analogues [41]. Simi-
larly, ATP-dependent ligases involve attack of a nucle-
ophilic substrate on an electrophilic acyl phosphate
[42] via a tetrahedral intermediate. These ligases are
inhibited by stable analogues of this intermediate [43–
45]. Original work on this type of analogue based on
glutathionylspermidine was carried out on EcGspS
[46,47]. These studies investigated GSH–Spd conju-
gates (Fig. 1), with the objective of developing enzyme
inhibitors that block the biosynthesis of trypanothione
[46–51]. The synthetase activity of EcGspS was inhib-
ited by a phosphonate tetrahedral mimic, in a noncom-
petitive, time-independent manner with Ki   10 lm
[47], and more potently by the phosphinate analogue
in a time-dependent manner with Ki
* =8n m [46,50].
In each case, the phosphorus-based pseudopeptide had
no effect on the amidase activity.
Here we examined the kinetic mechanism of CfGspS
and determined the modality of inhibition and potency
of these compounds against CfGspS and the homo-
logous enzyme TryS from various disease-causing
parasites.
Results
Initial velocity analysis of the kinetic mechanism
of GspS
A matrix of kinetic data was collected in order to deter-
mine the kinetic mechanism of GspS. Six families of
kinetic data were generated where each ligand (GSH,
Spd and ATP) was treated as the varied substrate at
different ﬁxed concentrations of another substrate, main-
taining a constant saturating concentration of the third
substrate [52–55]. The corresponding double reciprocal
plots of the data are shown in Fig. 2. A ping-pong
mechanism can be ruled out, as the ﬁtted lines of the
Lineweaver–Burk plots converge with each combination
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the 16 possible models for rapid equilibrium ter-
reactant systems were tested, including random,
ordered, and hybrid random–ordered [52]. Statistical
tests of each ﬁt revealed that the rapid equilibrium
random ter-ter model [see Eqn (1), Experimental pro-
cedures] ﬁtted signiﬁcantly better than any other of
the 15 models (P <1 0
)12). The interaction factors
were close to unity in this model, and when the inter-
action factors were set a = b = c = 1, the two ﬁts
were not signiﬁcantly different (P > 0.05), but did
return   10-fold lower standard errors for the binding
constants. Thus, the simplest model compatible with
the data suggests that substrates bind to GspS in any
order, without affecting binding of the other substrates,
to form a quaternary complex, enzyme–GSH–ATP–
Spd. When a = b = c = 1, the equilibrium dissocia-
tion constants for the binding of substrate to the free
enzyme are 609 ± 26, 157 ± 5 and 215 ± 8 lm for
GSH, Spd and ATP, respectively, and kcat = 22.8 ±
0.6 s
)1. When GSH and ATP were varied in a constant
ratio (10 : 1) versus various concentrations of Spd,
they produced a series of Lineweaver–Burk plots that
clearly converged (Fig. 3). This indicates that a product
release step does not occur between the binding of ATP
or GSH and Spd. Thus, the proposed kinetic model
for GspS is consistent with a random ter-reactant
mechanism, as shown in Fig. 4A.
Inhibition by phosphonate analogue
The compounds used in this study were designed to
mimic the unstable tetrahedral intermediate formed
during GspS-catalysed synthesis of glutathionylspermi-
dine (Fig. 1). However, as reported for EcGspS [47],
no time-dependent inhibition of CfGspS was observed
with the phosphonate mimic (Fig. 5), which suggests
that this compound is not acting as a mimic of the
unstable intermediate, but as a bisubstrate analogue
[56] incorporating key functional groups of both GSH
and Spd in the inhibitor. This compound behaves as a
modest classical linear competitive inhibitor of GspS
with respect to GSH (Fig. 5B) with a Ki of
156 ± 13 lm. Note that for classical reversible inhibi-
tors, the rate of product formation is constant pro-
vided that there is no signiﬁcant depletion of substrate
or inhibition by product.
Inhibition by phosphinate analogue
In contrast to the simple, linear inhibition shown by the
phosphonate, time-dependent inhibition was observed
for the phosphinate mimic (Fig. 6A). In reaction mix-
tures containing a slow-binding inhibitor initiated by
the addition of enzyme, the initial velocity v0 is indepen-
dent of inhibitor concentration, but decreases to a
slower steady-state velocity vs that is dependent on
inhibitor concentration [41]. These results are consistent
with glutathionylspermidine-dependent phosphoryla-
tion of the phosphinate (Fig. 4B), as previously demon-
strated for the inhibition of EcGspS [34,46,50]. The
progress curves for each phosphinate concentration
were ﬁtted to Eqn (3) (Experimental procedures) to
obtain values for v0, vs and kobs. Values for kobs were
then plotted against the inhibitor concentration
(Fig. 6B). A linear dependency between [I] and kobs was
observed, and was ﬁtted to Eqn (4) (Experimental
procedures) to obtain estimates for k3¢ and k4. The
progress curves used to determine the kobs values
were obtained at [S]⁄Km for GSH of 1.64. The rate
constant k3¢ (2.64 · 10
4 m
)1Æs
)1) was subsequently
corrected for competition by substrate, yielding
k3 = 6.98 · 10
4 m
)1Æs
)1 (k3 = k3¢[1 + [S]⁄Km]). The
y-intercept of Fig. 6B yields an estimate of k4 of
1.3 · 10
)3Æs
)1. Thus, the overall dissociation half-life
for the complex is 0.14 h (enzyme–inhibitor complex
half-life values were calculated as the ratio of 0.693⁄k4).
For an inhibitor of this type, the dissociation constant
(Ki) is then obtained from the ratio of k4⁄k3, yielding a
Ki of 18.6 nm. To conﬁrm the Ki value, v0 and vs
obtained at different concentrations of inhibitor were
ﬁtted to the equation vs = v0⁄(1 + [I]⁄Ki
app) by nonlin-
ear regression, yielding a Ki
app value of 31.1 ± 2.1 nm,
and true Ki value was calculated to be 19.0 ± 1.3 nm,
using the relationship Ki = Ki
app⁄(1 + [S]⁄Km). Thus
both methods of determining Ki are in excellent
agreement.
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pendent estimate of k4. In this method, the enzyme was
preincubated with excess inhibitor ([I] ‡ 10 [E]), and
the reaction was then initiated with substrate. Under
these conditions, a slow release of inhibitor is observed
until a steady state is reached. Provided that there is
no signiﬁcant enzyme inactivation, substrate depletion
or product inhibition, this steady state should be iden-
tical to the steady state established when initiating with
enzyme [57]. High concentrations of enzyme and inhib-
itor were preincubated for 1 h to allow the system to
reach equilibrium. Subsequent dilution into a large
volume of assay mix containing saturating substrate
concentrations causes dissociation of the enzyme–
inhibitor complex with regain of activity. Under these
conditions, provided that the initial rate v0 and the
effective inhibitor concentration are approximately
equal to zero, the rate of recovery of full enzyme activ-
ity will provide k4. When maintaining [I]>[ E]
([I] = 250 nm,[ E] = 20 nm), it proved impossible to
measure enzyme activity upon 100-fold dilution into
the assay mixture. Instead, high concentrations of
inhibitor (200 lm), enzyme (20 lm) and ATP (400 lm)
were preincubated on ice for 60 min and then applied
to a desalting column to remove all free inhibitor. The
following reactions were then analysed: (a) enzyme-
only control (Fig. 7, open circles); (b) the complete
inhibition reaction, enzyme + inhibitor + ATP (Fig. 7,
open squares); and (c) inhibitor-only control added to
an equal volume of the enzyme-only control sample
(Fig. 7, closed circles). The inhibitor-only control
progress curve is linear and matches that of the
enzyme-only control, demonstrating that essentially no
inhibitor has passed through the resin. The regain of
activity experiment (Fig. 7, open squares) clearly shows
that an enzyme-bound inhibitor complex passes
through the column and undergoes very slow dissocia-
tion upon dilution into the assay mixture. Under these
conditions, both v0 and the free inhibitor concentration
should be negligible in the ﬁnal assay, so that the rate
of recovery of activity provides the value for k4. After
ﬁtting of the data to Eqn (3) (Experimental pro-
cedures), a k4 value of 1.36 ± 0.06 · 10
)3Æs
)1 was
obtained, in excellent agreement with the value
obtained previously by varying the concentration of
phosphinate and initiating with enzyme.
Modality of inhibition
The mode of inhibition of the slow-binding phosphi-
nate was determined by examining the effect of varying
each substrate on the value of kobs at a ﬁxed inhibitor
concentration [58]. For a competitive inhibitor, kobs
decreases in a hyperbolic fashion with increasing
A 
B 
Fig. 4. Model of ter-reactant mechanism of
GspS catalysis and postulated slow-binding
inhibition by the phosphinate mimic. (A)
Kinetic mechanism. KGSH, KSpd and KATP are
the equilibrium dissociation constants for
the binding of substrate to free GspS (E).
(B) Postulated structure of the phosphory-
lated phosphinate mimic.
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GSH or Spd as varied substrate (Fig. 8, closed and
opened circles). For a noncompetitive inhibitor, kobs is
independent of substrate concentration (i.e. kobs = k),
whereas for an uncompetitive inhibitor, kobs increases
in a hyperbolic fashion with increasing concentrations
of substrate. As kobs increases with increasing concen-
trations of ATP (Fig. 8, closed squares), this suggests
uncompetitive inhibition. These data were then ﬁtted
to the appropriate equation for either competitive inhi-
bition [Eqn (5), Experimental procedures] or uncom-
petitive inhibition [Eqn (6), Experimental procedures].
The respective Km values for GSH, Spd and ATP are
400 ± 80 lm, 120 ± 40 lm and 130 ± 26 lm,i n
reasonable agreement with the respective Km values
determined directly in the substrate matrix experiment
above. Thus, the phosphinate inhibitor behaves as a
slow-binding competitive bisubstrate inhibitor with
respect to GSH and Spd, but not ATP. The latter
observation is consistent with the hypothesis that an
electrophilic acyl phosphate is formed by reaction of
ATP and GSH. The acyl phosphate then reacts with
Spd to form an unstable tetrahedral intermediate,
which is mimicked by the stable tetrahedral phosphi-
nate inhibitor. The nucleotide is not a component of
the unstable tetrahedral intermediate, and therefore the
Ki of 156 ± 13 µM
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ATP in binding to the enzyme.
To determine whether the phosphinate is turned
over by CfGspS in the presence of ATP, the activity of
the enzyme (100 nm) was determined in the absence of
GSH or Spd plus or minus 1 lm phosphinate over
30 min. After correction for the background rate due
to auto-oxidation of NADPH and hydrolysis of ATP
in the coupling system, the net rates of endogenous
ATPase activity (  0.01% of kcat) in the presence and
absence of inhibitor are 1.4 (± 0.9) · 10
)3 and
3.0 (± 1.5) · 10
)3Æs
)1, respectively (mean of three
determinations). This shows that the inhibitor is not
turned over by the enzyme. However, this method is
insufﬁciently sensitive to detect a single phosphoryla-
tion event.
Inhibition of TryS with phosphinate
Having established that CfGspS is potently inhibited
by the phosphinate inhibitor, it remained to be deter-
mined whether the homologous enzyme, TryS, could
also be inhibited in a similar manner. Owing to the
various pH optima, Km values for substrates and GSH
substrate inhibition proﬁles of the various TryS
enzymes to be compared (C. fasciculata, L. major,
T. cruzi and T. brucei), a uniform assay was used for
IC50 determination, i.e. 2 mm Spd, 0.2 mm GSH,
2m m ATP, 100 mm (K
+) Hepes (pH 7.2). This allows
for direct comparison of the data collected for all the
enzymes under conditions that approximate to the
physiological metabolite levels found in these organ-
isms [59]. In this study, IC50 values, slope factors and
Ki
app values were determined and found to be 20–40-
fold less that that of CfGspS (Table 1). In all cases,
the slope factor was approximately 1, indicating simple
binding at a single site for all the enzymes tested.
Discussion
An understanding of the kinetic and chemical mecha-
nism of GspS and TryS involved in the biosynthesis of
glutathionylspermidine and trypanothione is crucial for
the design of inhibitors against these potential drug
targets. TryS is particularly challenging in this respect,
as these enzymes display pronounced high substrate
inhibition by GSH and form glutathionylspermidine as
an intermediate [17–19]. CfGspS does not display
substrate inhibition by GSH [35,60], and therefore
provides a convenient simple model for this class of
ATP-dependent C-N ligases.
The kinetic dataset for CfGspS ﬁts best to a rapid
equilibrium random ter-ter reaction mechanism, and
deﬁnitively excludes a mechanism where either: (a)
ADP is released after phosphorylation of GSH prior
to binding of Spd; or (b) ADP is released following
formation of a phosphorylated enzyme intermediate
(ping-pong) prior to binding of GSH or Spd. In this
respect, the mechanism for CfGspS is similar to that
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showing that unbound inhibitor is completely removed using the
column method, d), The rate constant associated with the regener-
ation of enzymatic activity (k4) was determined as described in the
text.
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However, unlike the case with c-glutamylcysteine syn-
thetase, we did not detect any marked inﬂuence of
prior binding of one substrate on the equilibrium dis-
sociation constants of the other substrates [that is, the
interaction factors a, b and c were all close to unity,
and statistical analysis did not favour their inclusion in
Eqn (1)] (Experimental procedures) [52].
Our results are also broadly in agreement with a
previous study which concluded that partially puriﬁed
CfGspS follows a rapid equilibrium random order
mechanism with interaction factors close to unity [37].
However, we were unable to reconcile the peptide
sequence data reported by Flohe ´ et al. with our own,
as it corresponded to our sequence for CfTryS. This
discrepancy was later corrected in an erratum by
Flohe ´ ’s group [36], but raised a second discrepancy
concerning CfTryS. In our hands, heterologous expres-
sion of CfTryS did not yield active proteins, whereas
Flohe ´ ’s group reported that authentic CfTryS was able
to catalyse the synthesis of trypanothione from GSH,
Spd and ATP [28], similar to our ﬁndings for TryS
from T. brucei, L. major and T. cruzi [17–19]. To
resolve this remaining discrepancy, we have repeated
our initial study. The newly cloned enzyme was found
to differ at position 89, with a serine replacing an
asparagine in the original construct (AF006615). The
homogeneously pure soluble protein was found to be
active with either GSH or glutathionylspermidine, and
the product with either substrate was conﬁrmed to be
trypanothione by HPLC analysis (data not shown).
The reason for our previous failure [27] to detect this
activity by heterologous expression in yeast is not
apparent, but may have been due to a cloning or PCR
error involving this S89N mutation. Nonetheless, we
now agree entirely with the report by Comini et al.
[28] that CfTryS is capable of catalysing both steps in
the biosynthesis of trypanothione from GSH and Spd.
A kinetic mechanism has not been determined for
the E. coli enzyme, but a reaction mechanism has been
proposed in which the glycine carboxylate of GSH is
initially phosphorylated by the c-phosphate of ATP to
form an acyl phosphate, and this is followed by nucleo-
philic attack of the N
1-primary amine of Spd on the
acyl phosphate, leading to the formation of an unsta-
ble tetrahedral intermediate [46,48,49]. Structural
studies on EcGspS in complex with substrates and
inhibitors provide strong support for this model
[34]. Of particular note was the observation that the
slow-binding phosphinate inhibitor [46,50] had been
phosphorylated by ATP to form the tetrahedral phos-
phinophosphate in the active site, as previously postu-
lated [51]. In addition, a disordered domain in the
apoenzyme was observed to adopt an ordered confor-
mation over the active site when bound with substrates
or inhibitor. Our kinetic studies indicate that all three
substrates have to bind to the enzyme prior to cataly-
sis. This suggests that formation of the quaternary
complex induces closure of the lid domain over the
active site to form a catalytically competent complex,
thereby preventing access of water to hydrolyse the
acyl phosphate intermediate.
Our kinetic analysis shows that the phosphonate
analogue displays classical, linear competitive inhibi-
tion with respect to GSH, with a modest Ki of 156 lm
against CfGspS, as compared to the mixed-type pat-
tern (Ki and Ki¢ of 6 and 14 lm, respectively) reported
for EcGspsS [47]. In contrast, the phosphinate displays
slow tight-binding inhibition with a Ki of 19 nm, simi-
lar to the Ki*o f8n m for the E. coli enzyme [46]. Our
studies also demonstrate that this inhibitor behaves as
a mimic of the unstable tetrahedral intermediate that is
proposed to form during the GspS-catalysed reaction
as originally postulated [51]. At ﬁrst sight, the uncom-
petitive behaviour of the phosphinate inhibitor rather
than noncompetitive behaviour is not consistent with a
rapid equilibrium random mechanism. However, such
an inhibition pattern would be expected if the inhibitor
underwent binding followed by a single phosphoryla-
tion event, as suggested by the kinetic behaviour
Table 1. Inhibition constants of phosphinate against GspS and various TryS enzymes. All assays were performed under conditions approxi-
mating to the intracellular physiological state (i.e. pH 7.2, 2 mM Spd, 0.2 mM GSH and 2 mM Mg
2+-ATP), and were initiated with 100 nM
each enzyme in the presence of various phosphinate concentrations. IC50 values and slope factors are from the inhibition proﬁles determined
from Eqn (7), and Ki
app values were determined from the tight-binding inhibition equation (Eqn 8). The errors represent the standard error of
the ﬁt to the appropriate equation.
Inhibition constants
Enzyme
CfGspS CfTryS L. major TryS T. cruzi TryS T. brucei TryS
IC50 (nM) 72 ± 6 1380 ± 380 650 ± 25 530 ± 20 1300 ± 50
Slope factor 1.2 ± 0.1 1.1 ± 0.3 1.1 ± 0.04 1.1 ± 0.04 1.1 ± 0.05
Ki
app (nM) 29 ± 5 1330 ± 350 580 ± 30 490 ± 20 1200 ± 500
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ﬁrmed in the crystal structure of this inhibitor bound
in the active site of EcGspS [34]. The glutathionyl-
spermidine phosphinate analogue is also a potent
inhibitor of TryS enzymes from L. major, T. cruzi and
T. brucei; when assayed under identical conditions
approximating to intracellular concentrations, TryS
enzymes are approximately 20-fold less sensitive than
CfGspS. Although the phosphinate showed no growth-
inhibitory activity at 100 lm over 72 h of exposure
against L. major promastigotes, T. cruzi epimastigotes
and T. brucei procyclics, various chemical modiﬁca-
tions could enhance cellular penetration, e.g. acyloxy
ester prodrugs [61].
An alignment of EcGspS with CfGspS and other
TryS proteins reveals some other interesting features
(Fig. 9). First, despite the trypanosomatid proteins
having < 30% identity and < 45% similarity, all
three residues involved in binding Mg
2+ (green trian-
gles) and three of four involved in binding ATP (red
triangles) are absolutely conserved. Second, four of ﬁve
residues interacting with GSH (blue triangles) in the
productive binding mode are also conserved. Third,
two of three residues implicated in binding of the Spd
moiety of the phosphinate inhibitor (yellow triangles)
are also conserved. Fourth, Pai et al. also noted a non-
productive binding mode (black triangles), where GSH
forms a mixed disulﬁde with Cys338 and an isopeptide
bond between the glycine moiety of GSH and Lys607
of the protein. However, this is clearly not required for
catalysis in the trypanosomatid enzymes, as neither
residue is conserved in any of these enzymes. Finally,
the E. coli enzyme is a homodimer, whereas the try-
panosomatid TryS enzymes are monomeric, or hetero-
dimeric in the case of CfTryS and CfGspS. In this
case, the residues that interact between monomers in
EcGspS (black circles) are hardly conserved at all. One
other interesting difference between EcGspS and
CfGspS is that the latter enzyme has an additional 100
amino acids. The alignment in Fig. 9 highlights a num-
ber of insertions that are dispersed throughout the
sequence of CfGspS. These include an insertion of 17
amino acids in the amidase domain and two in the
synthetase domain (one of 14 amino acids and the
Fig. 9. Conservation of key functional residues identiﬁed for EcGspS in CfGspS and TryS. The GenBank⁄EMBL⁄DDBJ accession numbers
used to generate the alignment using T-COFFEE are: EcGspS (U23148), CfGspS (U66520), CfTryS (AF006615), L. major TryS (AJ311570),
T. cruzi TryS (AF311782) and T. brucei TryS (AJ347018). Absolutely conserved residues are marked in bold; coloured residues indicate side
chain interactions in EcGspS with substrates or inhibitors [33]. Green triangles, residues involved in binding Mg
2+; red triangles, three of four
residues involved in binding ATP; blue triangles, four of ﬁve residues interacting with GSH; yellow triangles, two of three residues implicated
in binding of the Spd moiety of the phosphinate inhibitor; black triangles, nonproductive binding mode, where GSH forms a mixed disulﬁde
with Cys338 and an isopeptide bond between the glycine moiety of GSH and Lys607 of the protein; black circles, residues that interact
between monomers in EcGspS. Only the relevant C-terminal region of the synthetase domain is shown.
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tional insertions in CfGspS are required for its hetero-
dimeric interactions with CfTryS.
From the above analysis, it is not immediately obvi-
ous why the phosphinate inhibitor is   20-fold less
potent against the TryS enzymes than against CfGspS
and EcGspS. Possibly, the substitution of Asp610,
which is involved in recognition of the N
8-amine of
Spd, for a proline in TryS (methionine in CfGspS) is a
critical factor. Alternatively, the fact that TryS has to
accommodate either N
1-glutathionylspermidine or
N
8-glutathionylspermidine as well as Spd in the poly-
amine-binding site may be a signiﬁcant factor. The
current ligand-free structure of L. major TryS [62] is
not helpful in resolving these issues, and substrates or
inhibitors in complex with TryS are needed. In the
meantime, the phosphinate inhibitors represent a valu-
able starting point for further development of drug-like
inhibitors against this target.
Experimental procedures
Materials
All chemicals were of the highest grade available from
Sigma-Aldrich (Gillingham, UK), Roche Diagnostics Ltd
(Burgess Hill, UK) or Calbiochem (Merck Biosciences,
Nottingham, UK). The phosphonate and phosphinate
analogues of glutathionylspermidine were synthesized as
previously described [49,51]. The structure and purity of
both compounds were conﬁrmed by NMR, high-resolution
MS and elemental analysis.
Expression and puriﬁcation of GspS
Recombinant GspS was prepared using a 60 L fermenter,
and puriﬁed to greater than 98% homogeneity as described
previously [35], except that a HiLoad Q Sepharose 16⁄10
column (GE Healthcare, Amersham, UK) was used in the
ﬁnal step. Active fractions were pooled, buffer was
exchanged into 100 mm (K
+) Hepes containing 0.01%
sodium azide, 1 mm dithiothreitol and 1 mm EDTA, and the
sample concentration was determined using the calculated
extinction coefﬁcient of 99 370 at 280 nm. Aliquots of GspS
were then ﬂash frozen and stored in aliquots at )80  C.
Expression and puriﬁcation of TryS enzymes
TryS enzymes from T. brucei, L. major and T. cruzi were
prepared as described previously [17–19]. In addition, we
were able to obtain functionally active CfTryS by generat-
ing a new construct in a modiﬁed pET15b vector in which
the thrombin cleavage site had been replaced by a TEV
protease cleavage site. The ORF was PCR ampliﬁed from
C. fasciculata genomic DNA using the sense primer 5¢-
CAT ATG GCG TCC GCT GAG CGT GTG CCG G-3¢,
which includes an NdeI site (underlined) and a start codon
(in bold), and the antisense primer 5¢-GGA TCC TTA CTC
ATC CTC GGC GAG CTT G-3¢, which includes a stop
codon (in bold) and a BamHI site (underlined); the PCR
product was subsequently cloned, via pCR-Blunt II-TOPO
(Invitrogen, Paisley, UK), into the NdeI⁄BamHI site of
pET15bTEV. Sequencing of three independent clones
revealed that the sequence was almost identical to the
sequence previously deposited for CfTryS (AF006615),
except that serine replaced asparagine at position 89 of the
ORF. This construct, CfTryS_pET15bTEV, was trans-
formed into BL21(DE3)pLysS-competent cells (Novagen,
Merck Biosciences); typically, cultures were then grown in
Terriﬁc Broth at 37  Ct oD600 nm ‡ 1.2, cooled to 22  C,
induced with a ﬁnal concentration of 0.5 mm isopropyl-
b-d-thiogalactoside, and grown for an additional 16 h.
Puriﬁcation of recombinant protein was achieved using two
chromatographic steps [5 mL His-Trap (GE Healthcare),
TEV protease cleavage (2 h, 30  C), followed by a HiLoad
Q Sepharose 16⁄10 HP column (GE Healthcare)].
Assay conditions for the kinetic mechanism
of GspS
All kinetic assays were performed at 25  C using an assay
system that couples ADP production to NADH oxidation at
340 nm [35]. Each assay contained 100 mm (K
+) Hepes
(pH 7.3), 0.2 mm NADH, 1 mm phosphoenolpyruvate,
5m m dithiothreitol or Tris(2-carboxyethyl)phosphine hydro-
chloride, 0.5 mm EDTA, 10 mm MgSO4,2U ÆmL
)1 l-lactate
dehydrogenase, and 2 UÆmL
)1 pyruvate kinase (both cou-
pling enzymes were from rabbit muscle, and purchased from
Roche), with varying amounts of ATP, GSH and Spd in a
total volume of 1 mL. Rates are expressed in moles of sub-
strate utilized per second per mole of enzyme. To determine
the kinetic mechanism, data were collected for GspS at a
range of substrate concentrations. A complete matrix of
rates as a function of substrate concentration (ATP, 31.25–
500 lm; GSH, 62.5–1000 lm; and Spd 62.5–1000 lm) was
gathered, so that for any given concentration of any one sub-
strate the rates were measured over the entire range of the
remaining two substrates. When ﬁxed concentrations of each
of these substrates were used, the ﬁnal concentrations for
ATP, GSH and Spd were 0.5, 1 and 1 mm respectively,
unless otherwise stated. The assay was initiated by adding
GspS (300 nm) and, after a lag of 10 s, the linear decrease in
absorbance was monitored for up to 1 min. Data were then
globally ﬁtted by nonlinear regression to all possible models
for rapid equilibrium ter-reactant systems [52]. The goodness
of ﬁt for each model was compared statistically using the
F-test and kinetic constants obtained by ﬁtting to Eqn (1):
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system, where KGSH, KSpd and KATP are the equilibrium disso-
ciation constants for the binding of substrate with free
enzyme, and a, b and c are the interaction factors between Spd
and ATP, GSH and ATP, and GSH and Spd, respectively.
Inhibitors and enzyme inhibition assays
Inhibitor studies employed the coupled assay described
above. Possible inhibition of the coupling enzyme system was
excluded by substituting glucose and hexokinase for GspS or
TryS in the assays, in which case no enzyme inhibition was
observed. Reactions were typically carried out as described
for the kinetic mechanism, with GSH and Spd (both at
1m m) and ATP (2 mm) concentrations kept constant. Sub-
strates and inhibitors were preincubated for 10 min before
initiation of the reaction with GspS (10–20 nm). Data for the
phosphonate analogue were ﬁtted to the Michaelis–Menten
equation for competitive inhibition (Eqn 2) when GSH was
varied, and analysed using the program grafit:
v ¼
Vmax  ½ S 
Km 1 þ ½I 
Ki
  
þ½ S 
ð2Þ
For time-dependent inhibition by the phosphinate ana-
logue, the progress curves at different inhibitor concentra-
tions can be described by Eqn (3):
P ½  ¼ vst þ½ ð v0   vsÞð1   e ktÞ =kobs ð3Þ
where [P] is the product concentration at time t, v0 and vs
are the initial and ﬁnal steady-state rates, and kobs is the
apparent ﬁrst-order rate constant for the establishment of
the ﬁnal steady-state equilibrium. The resulting values for
kobs were plotted as a function of inhibitor concentration,
I, and ﬁtted to Eqn (4) to obtain estimates of k3¢ and k4:
kobs ¼ k0
3½I þk4 ð4Þ
The rate constant k4, for the dissociation of the enzyme–
inhibitor complex, was also measured directly from the
time-dependent recovery of enzyme activity. GspS (20 lm)
was preincubated, with or without phosphinate (200 lm)
and Mg
2+-ATP (400 lm), in 30 lL of assay buffer at 4  C
for 1 h, in order to reach equilibrium. A sample containing
only inhibitor and Mg
2+-ATP sample was also included as
an internal control to verify efﬁcient retention of the phos-
phinate by the column. Following preincubation, samples
were applied to 0.5 mL of Zeba desalt spin columns
(Pierce) and centrifuged to remove unbound inhibitor
(1500 g, 2 min, 22  C). Subsequently, 2 lL of each sample
was diluted (1 : 500) into the complete enzyme assay mix-
ture and the absorbance change was monitored. The recov-
ery of enzymatic activity was measured at 340 nm using the
coupled assay described above.
To determine the modality of inhibition by the phosphi-
nate, assays were carried out in a reaction mixture of 1 mL
containing 1 lm inhibitor in addition to the other compo-
nents of the coupled assay. When GSH was varied, ATP
and Spd were kept constant at 2 and 10 mm respectively;
when Spd was varied, ATP and GSH were kept constant at
2 and 10 mm respectively; and when ATP was varied, GSH
and Spd were kept constant at 1 mm. The reaction mix was
left for 5 min at 25  C, and the reaction was then initiated
with CfGspS (20 nm) and monitored for 15 min. These
data were then ﬁtted to the appropriate equation [58] for
either competitive inhibition (Eqn 5)
kobs ¼
k
1 þð ½ S =KmÞ
ð5Þ
or uncompetitive inhibition (Eqn 6)
kobs ¼
k
1 þð Km=½S Þ
ð6Þ
where k is the value for kobs in the absence of substrate,
and Km is the binding constant for the varied substrate S.
IC50 data were also gathered for representative recombi-
nant TryS enzymes (T. cruzi, T. brucei and L. major) [17–
19], using more physiological-like conditions, i.e. 2 mm
Spd, 0.2 mm GSH, 2 mm ATP, and 100 mm (K+) Hepes
(pH 7.2) (the remainder of the components of the coupled
assay were as previously above) and various phosphinate
concentrations (0–10 lm). Reactions were initiated using
100 nm each enzyme, and the change in absorbance was
monitored for 30 min. The resulting steady-state rates were
then ﬁtted to the following two-parameter equation
(Eqn 7), where the lower data limit is 0, i.e. the data are
background corrected, and the upper data limit is 100, i.e.
the data are range corrected.
y ¼
100%
1 þ ½I 
IC50
   s ð7Þ
In this equation, s is a slope factor. The equation
assumes that y falls with increasing [I]. The Ki
app values of
t
t
Vmax
¼
GSH ½  Spd ½  ATP ½ 
abcKGSHKSpdKATP
1 þ
GSH ½ 
KGSH
þ
Spd ½ 
KSpd
þ
ATP ½ 
KATP
þ
GSH ½  Spd ½ 
cKGSHKSpd
þ
GSH ½  ATP ½ 
bKGSHKATP
þ
Spd ½  ATP ½ 
aKSpdKATP
þ
GSH ½  Spd ½  ATP ½ 
abcKGSHKSpdKATP
ð1Þ
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the following tight-binding inhibition equation [41] (Eqn 8),
where the enzyme concentration [E] was ﬁxed at 100 nm:
vi
v0
¼1 
ð½E þ½I þK
app
i Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½E þ½I þK
app
i Þ
2 4½E ½I 
q
2½E 
ð8Þ
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